Science
Alzheimer's Drug Lecanemab Shows 27% Cognitive Decline Reduction in Major Clinical Trial
Lecanemab shows 27% reduction in cognitive decline for early Alzheimer's patients. The breakthrough could transform dementia treatment worldwide.
2 articles
Lecanemab shows 27% reduction in cognitive decline for early Alzheimer's patients. The breakthrough could transform dementia treatment worldwide.
Amazon's pharmacy push threatens traditional drugstore chains as the tech giant expands prescription services nationwide. CVS and Walgreens scramble to adapt.